On September 17, the signing meeting of “CONX” household 12-channel electrocardiograph (ECG) was held in the conference room of Liaoning Pharmaceutical Foreign Trade Corporation. Zhang Jie, Deputy General Manager of Liaoning Medical Trade and Head of SHANGHAI PHARMA Tongshan Pharmacy, Ma Rui, Liaoning Cardiorenal Metabolic Syndrome Regional Manager of North China Area II, AstraZeneca (China) Pharmaceutical Cardiovascular Division, and Weng Jie, Marketing Director of CardioCloud Medical Technology (Beijing) Co., Ltd. attended the signing ceremony and reached a cooperative consensus on the goal of “bringing all-round care to cardiovascular patients with medicines, equipment, and treatment”. SHANGHAI PHARMA Tongshan Pharmacy is the first one to sign the contract of this equipment in 8 provinces of North China.
As a service platform focusing on people’s health, SHANGHAI PHARMA Tongshan Pharmacy has been committed to exploring how to meet people’s growing needs for health. The introduction of the ECG monitoring equipment has truly realized the whole-course health management of crisis prevention and recovery after the illness for people with potential cardiovascular disease risks and those with existing diseases, and provides those people with overall solutions of remote diagnosis and treatment, health consultation, and follow-up guidance to escort the people’s life and health with professional services.
Vascular disease is a serious threat to the people’s life and health, and is the primary cause of death and disease burden of Chinese residents. According to the “Report on Cardiovascular Health and Diseases in China” (2019) released by the National Center for Cardiovascular Diseases, the prevalence rate of cardiovascular diseases in China is on the rise, with 330 million people now suffering from cardiovascular diseases. Because the majority of patients cannot be monitored at all time, and it is difficult to capture the disease state by a standard electrocardiogram, the disease cannot be treated in time and effectively. Therefore, the risk assessment and risk factor management of cardiovascular diseases are essential for the prevention of cardiovascular diseases, and real-time ECG monitoring of patients is of great significance for timely detection of disease risks.
“CONX” BEP186 medical wearable 12-channel dynamic electrocardiograph is especially designed for family use. It is a key research and development project of the Ministry of Science and Technology, and won the second prize of Military Science and Technology Progress Award and the second prize of National Science and Technology Progress Award in 2017 and 2019. This product has changed the traditional mode of cardiac examination without the time and place restrictions, ordinary people can carry out self-examination, and the generated test reports can be evaluated and reviewed by professional doctors. In case of a critical illness, the evaluating doctor will notify the patient or his family member as soon as possible to help the patient monitor to abnormal ECG in real time. It can suggest the potential risk of acute myocardial infarction and other high-risk cardiovascular diseases, so as to provide convenience for out-of-hospital cardiovascular disease health care. A perfect closed loop will be achieved in the aspects of pre-disease prevention, in-disease detection and post-disease follow-up.